Review found that cytochrome P450 pharmacogenetic testing in adults entering antipsychotic treatment for schizophrenia may show promise in terms of predicting adverse drug reactions such as tardive dyskinesia but further evidence for clinical effectiveness and cost-effectiveness is required.